Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity, and calvarial defects in mice

DMM Disease Models and Mechanisms

Volumn 6, Issue 6, 2013, Pages 1448-1458

  Lapinski, Philip E ^a   Meyer, Melissa F ^a   Feng, Gen Sheng ^b   Kamiya, Nobuhiro ^c   King, Philip D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCALCIN; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 2; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BONE DEFECT; BONE DEVELOPMENT; CALVARIAL DEFECT; CARTILAGE CELL; CELL DIFFERENTIATION; CHONDRODYSPLASIA; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICAL BONE; ENCHONDRAL OSSIFICATION; FEMALE; FUNNEL CHEST; GENE DELETION; GROWTH RETARDATION; LIMB DEFORMITY; LIPODYSTROPHY; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOBLAST; PIGEON THORAX; POSTNATAL GROWTH; PRIORITY JOURNAL; PROGENY; PROMOTER REGION; THORAX DEFORMITY; TRABECULAR BONE;

ANIMALS; BONE AND BONES; FETAL GROWTH RETARDATION; LIMB DEFORMITIES, CONGENITAL; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; THORAX;

EID: 84888864503     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.012849     Document Type: Article

References (61)

1. Araki, T., Mohi, M. G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., Yang, W., Pao, L. I., Gilliland, D. G., Epstein, J. A. et al. (2004). Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 10, 849-857.
2. Arrandale, J. M., Gore-Willse, A., Rocks, S., Ren, J. M., Zhu, J., Davis, A., Livingston, J. N. and Rabin, D. U. (1996). Insulin signaling in mice expressing reduced levels of Syp. J. Biol. Chem. 271, 21353-21358.
3. Asagiri, M. and Takayanagi, H. (2007). The molecular understanding of osteoclast differentiation. Bone 40, 251-264.
4. Barford, D. and Neel, B. G. (1998). Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 6, 249-254.
5. Bauler, T. J., Kamiya, N., Lapinski, P. E., Langewisch, E., Mishina, Y., Wilkinson, J. E., Feng, G. S. and King, P. D. (2011). Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations. Dis. Model. Mech. 4, 228-239.
6. Binder, G., Neuer, K., Ranke, M. B. and Wittekindt, N. E. (2005). PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J. Clin. Endocrinol. Metab. 90, 5377-5381.
7. Bowen, M. E., Boyden, E. D., Holm, I. A., Campos-Xavier, B., Bonafé, L., Superti-Furga, A., Ikegawa, S., Cormier-Daire, V., Bovée, J. V., Pansuriya, T. C. et al. (2011). Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet. 7, e1002050.
8. Buday, L. and Downward, J. (2008). Many faces of Ras activation. Biochim. Biophys. Acta 1786, 178-187.
9. Chong, Z. Z. and Maiese, K. (2007). The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol. Histopathol. 22, 1251-1267.
10. Choudhry, K. S., Grover, M., Tran, A. A., O'Brian Smith, E., Ellis, K. J. and Lee, B. H. (2012). Decreased bone mineralization in children with Noonan syndrome: another consequence of dysregulated RAS MAPKinase pathway? Mol. Genet. Metab. 106, 237-240.
11. Dance, M., Montagner, A., Salles, J. P., Yart, A. and Raynal, P. (2008). The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell. Signal. 20, 453-459.
12. De Rocca Serra-Nédélec, A., Edouard, T., Tréguer, K., Tajan, M., Araki, T., Dance, M., Mus, M., Montagner, A., Tauber, M., Salles, J. P. et al. (2012). Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature. Proc. Natl. Acad. Sci. USA 109, 4257-4262.
13. Digilio, M. C., Conti, E., Sarkozy, A., Mingarelli, R., Dottorini, T., Marino, B., Pizzuti, A. and Dallapiccola, B. (2002). Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am. J. Hum. Genet. 71, 389-394.
14. Digilio, M. C., Sarkozy, A., de Zorzi, A., Pacileo, G., Limongelli, G., Mingarelli, R., Calabrò, R., Marino, B. and Dallapiccola, B. (2006). LEOPARD syndrome: clinical diagnosis in the first year of life. Am. J. Med. Genet. 140A, 740-746.
15. Edouard, T., Combier, J. P., Nédélec, A., Bel-Vialar, S., Métrich, M., Conte-Auriol, F., Lyonnet, S., Parfait, B., Tauber, M., Salles, J. P. et al. (2010). Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factorinduced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling. Mol. Cell. Biol. 30, 2498-2507.
16. Fragale, A., Tartaglia, M., Wu, J. and Gelb, B. D. (2004). Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum. Mutat. 23, 267-277.
17. Gorlin, R. J., Anderson, R. C. and Blaw, M. (1969). Multiple lentigenes syndrome. Am. J. Dis. Child. 117, 652-662.
18. Hakak, Y., Hsu, Y. S. and Martin, G. S. (2000). Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt. Oncogene 19, 3164-3171.
19. Hanna, N., Montagner, A., Lee, W. H., Miteva, M., Vidal, M., Vidaud, M., Parfait, B. and Raynal, P. (2006). Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Lett. 580, 2477-2482.
20. He, Z., Zhu, H. H., Bauler, T. J., Wang, J., Ciaraldi, T., Alderson, N., Li, S., Raquil, M. A., Ji, K., Wang, S. et al. (2013). Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase. Proc. Natl. Acad. Sci. USA 110, E79-E88.
21. Ho, I. C., O'Donnell, D. and Rodrigo, C. (1989). The occurrence of supernumerary teeth with isolated, nonfamilial leopard (multiple lentigines) syndrome: report of case. Spec. Care Dentist. 9, 200-202.
22. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J. and Shoelson, S. E. (1998). Crystal structure of the tyrosine phosphatase SHP-2. Cell 92, 441-450.
23. Jongmans, M., Sistermans, E. A., Rikken, A., Nillesen, W. M., Tamminga, R., Patton, M., Maier, E. M., Tartaglia, M., Noordam, K. and van der Burgt, I. (2005). Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature. Am. J. Med. Genet. A. 134A, 165-170.
24. Keilhack, H., David, F. S., McGregor, M., Cantley, L. C. and Neel, B. G. (2005). Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J. Biol. Chem. 280, 30984-30993.
25. Kennedy, L. A. (1983). Metachondromatosis. Radiology 148, 117-118.
26. Kim, H. K., Aruwajoye, O., Sucato, D., Richards, B. S., Feng, G. S., Chen, D., King, P. and Kamiya, N. (2013a). Induction of SHP2-deficiency in chondrocytes causes severe scoliosis and kyphosis in mice. Spine [Epub ahead of print] PMID: 23873233.
27. Kim, H. K., Feng, G. S., Chen, D., King, P. D. and Kamiya, N. (2013b). Targeted disruption of Shp2 in chondrocytes leads to metachondromatosis with multiple cartilaginous protrusions. J. Bone Miner. Res. [Epub ahead of print] doi: 10.1002/jbmr.2062.
28. Kita, K., Kimura, T., Nakamura, N., Yoshikawa, H. and Nakano, T. (2008). PI3K/Akt signaling as a key regulatory pathway for chondrocyte terminal differentiation. Genes Cells 13, 839-850.
29. Kontaridis, M. I., Eminaga, S., Fornaro, M., Zito, C. I., Sordella, R., Settleman, J. and Bennett, A. M. (2004). SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway. Mol. Cell. Biol. 24, 5340-5352.
30. Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D. and Neel, B. G. (2006). PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281, 6785-6792.
31. Lee, C. K., Chang, B. S., Hong, Y. M., Yang, S. W., Lee, C. S. and Seo, J. B. (2001). Spinal deformities in Noonan syndrome: a clinical review of sixty cases. J. Bone Joint Surg. Am. 83-A, 1495-1502.
32. Legius, E., Schrander-Stumpel, C., Schollen, E., Pulles-Heintzberger, C., Gewillig, M. and Fryns, J. P. (2002). PTPN11 mutations in LEOPARD syndrome. J. Med. Genet. 39, 571-574.
33. Limal, J. M., Parfait, B., Cabrol, S., Bonnet, D., Leheup, B., Lyonnet, S., Vidaud, M. and Le Bouc, Y. (2006). Noonan syndrome: relationships between genotype, growth, and growth factors. J. Clin. Endocrinol. Metab. 91, 300-306.
34. Logan, M., Martin, J. F., Nagy, A., Lobe, C., Olson, E. N. and Tabin, C. J. (2002). Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis 33, 77-80.
35. Maekawa, M., Ishizaki, T., Boku, S., Watanabe, N., Fujita, A., Iwamatsu, A., Obinata, T., Ohashi, K., Mizuno, K. and Narumiya, S. (1999). Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 285, 895-898.
36. Marin, T. M., Keith, K., Davies, B., Conner, D. A., Guha, P., Kalaitzidis, D., Wu, X., Lauriol, J., Wang, B., Bauer, M. et al. (2011). Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest. 121, 1026-1043.
37. Martinelli, S., Torreri, P., Tinti, M., Stella, L., Bocchinfuso, G., Flex, E., Grottesi, A., Ceccarini, M., Palleschi, A., Cesareni, G. et al. (2008). Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum. Mol. Genet. 17, 2018-2029.
38. Martínez-Quintana, E. and Rodríguez-González, F. (2012). LEOPARD syndrome: clinical features and gene mutations. Mol. Syndromol. 3, 145-157.
39. Matozaki, T., Murata, Y., Saito, Y., Okazawa, H. and Ohnishi, H. (2009). Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci. 100, 1786-1793.
40. Matsushita, T., Chan, Y. Y., Kawanami, A., Balmes, G., Landreth, G. E. and Murakami, S. (2009). Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol. Cell. Biol. 29, 5843-5857.
41. Mukherjee, A., Wilson, E. M. and Rotwein, P. (2010). Selective signaling by Akt2 promotes bone morphogenetic protein 2-mediated osteoblast differentiation. Mol. Cell. Biol. 30, 1018-1027.
42. Noonan, J. A. (2006). Noonan syndrome and related disorders: alterations in growth and puberty. Rev. Endocr. Metab. Disord. 7, 251-255.
43. Noonan, J. A., Raaijmakers, R. and Hall, B. D. (2003). Adult height in Noonan syndrome. Am. J. Med. Genet. A. 123A, 68-71.
44. Noordam, C., Peer, P. G., Francois, I., De Schepper, J., van den Burgt, I. and Otten, B. J. (2008). Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, nonreceptor- type 11. Eur. J. Endocrinol. 159, 203-208.
45. Ohashi, K., Nagata, K., Maekawa, M., Ishizaki, T., Narumiya, S. and Mizuno, K. (2000). Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J. Biol. Chem. 275, 3577-3582.
46. Oliver, J. A., Stolberg, V. R., Chensue, S. W. and King, P. D. (2012). IL-4 acts as a potent stimulator of IFN-γ expression in CD8+ T cells through STAT6-dependent and independent induction of Eomesodermin and T-bet. Cytokine 57, 191-199.
47. Peng, X. D., Xu, P. Z., Chen, M. L., Hahn-Windgassen, A., Skeen, J., Jacobs, J., Sundararajan, D., Chen, W. S., Crawford, S. E., Coleman, K. G. et al. (2003). Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 17, 1352-1365.
48. Sarkozy, A., Conti, E., Digilio, M. C., Marino, B., Morini, E., Pacileo, G., Wilson, M., Calabrò, R., Pizzuti, A. and Dallapiccola, B. (2004). Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome. J. Med. Genet. 41, e68.
49. Saxton, T. M., Ciruna, B. G., Holmyard, D., Kulkarni, S., Harpal, K., Rossant, J. and Pawson, T. (2000). The SH2 tyrosine phosphatase shp2 is required for mammalian limb development. Nat. Genet. 24, 420-423.
50. Saxton, T. M., Henkemeyer, M., Gasca, S., Shen, R., Rossi, D. J., Shalaby, F., Feng, G. S. and Pawson, T. (1997). Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. 16, 2352-2364.
51. Schmittgen, T. D. and Livak, K. J. (2008). Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101-1108.
52. Sharland, M., Burch, M., McKenna, W. M. and Paton, M. A. (1992). A clinical study of Noonan syndrome. Arch. Dis. Child. 67, 178-183.
53. Tartaglia, M., Kalidas, K., Shaw, A., Song, X., Musat, D. L., van der Burgt, I., Brunner, H. G., Bertola, D. R., Crosby, A., Ion, A. et al. (2002). PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am. J. Hum. Genet. 70, 1555-1563.
54. Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., Burgt, I., Palleschi, A., Petrucci, T. C. et al. (2006). Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet. 78, 279-290.
55. Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S. et al. (2001). Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29, 465-468.
56. Tartaglia, M., Zampino, G. and Gelb, B. D. (2010). Noonan syndrome: clinical aspects and molecular pathogenesis. Mol. Syndromol. 1, 2-26.
57. Wu, C. J., O'Rourke, D. M., Feng, G. S., Johnson, G. R., Wang, Q. and Greene, M. I. (2001). The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene 20, 6018-6025.
58. Yang, W., Wang, J., Moore, D. C., Liang, H., Dooner, M., Wu, Q., Terek, R., Chen, Q., Ehrlich, M. G., Quesenberry, P. J. et al. (2013). Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. Nature 499, 491-495.
59. Yu, Z. H., Xu, J., Walls, C. D., Chen, L., Zhang, S., Zhang, R., Wu, L., Wang, L., Liu, S. and Zhang, Z. Y. (2013). Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. J. Biol. Chem. 288, 10472-10482.
60. Zenker, M., Buheitel, G., Rauch, R., Koenig, R., Bosse, K., Kress, W., Tietze, H. U., Doerr, H. G., Hofbeck, M., Singer, H. et al. (2004). Genotype-phenotype correlations in Noonan syndrome. J. Pediatr. 144, 368-374.
61. Zhang, E. E., Chapeau, E., Hagihara, K. and Feng, G. S. (2004). Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism. Proc. Natl. Acad. Sci. USA 101, 16064-16069.